logo.png

  • HOME

  • ABOUT US

    • SOCIAL IMPACT

  • STRATEGY

    • GENE THERAPY
    • CELL THERAPY
    • RNA-BASED THERAPY
    • TARGETED THERAPIES
    • MICROBIOME

  • TEAM

  • PORTFOLIO

    • VENTURE PORTFOLIO
    • PAST PORTFOLIO

  • 4BATLE ICAV

  • NEWS ROOM

  • CONTACT

  • More

    Use tab to navigate through the menu items.

    NEWS ROOM

    • Mar 24, 2018

    TiGenix and Takeda announce Alofisel® (darvadstrocel) receives approval

    TiGenix and Takeda announce Alofisel® (darvadstrocel) receives approval
    • Jan 5, 2018

    Takeda announces its intention to acquire TiGenix

    Takeda announces its intention to acquire TiGenix
    ARCHIVE
    • April 2022
    • March 2022
    • February 2022
    • January 2022
    • December 2021
    • October 2021
    • April 2021
    • March 2021
    • January 2021
    • December 2020
    • November 2020
    • October 2020
    • July 2020
    • June 2020
    • May 2020
    • March 2020
    • November 2019
    • September 2019
    • February 2019
    • November 2018
    SEARCH BY TAGS
    • portfolio
    • 4BIO Ventures II
    • Orchard Therapeutics
    • appointment
    • investment
    • approval
    • collaboration
    • advisory board
    • SparingVision
    • Spark Therapeutics
    • Takeda
    • AAV
    • acquisition
    • ADC Therapeutics
    • CodeBio
    • IPO
    • publication
    • Ray Therapeutics
    • review
    • TiGenix
    • 4BATLE
    • AI
    • awards
    • BLA
    • Carisma
    • clinical trials
    • EGLS
    • ETF
    • grant
    • Harbor Capital
    • Insig AI
    • Intellia
    • Kyowa Kirin
    • Moderna
    • pricing
    • Redpin Therapeutics
    • results
    • venture
    FOLLOW US
    PRI-Sig-Web-V1.png
    4BIO Capital is a trading name of 4BIO Partners LLP which is authorised and regulated by the Financial Conduct Authority (Reference Number 842764)

    4BIO Partners LLP is an SEC Registered Investment Advisor number 801-121342
    LEGAL
    © 2015-2022 by 4BIO Partners LLP